Login to Your Account



FOLLOW-UP PHASE III STRONG

‘Capacity’ to ASCEND: Intermune’s win in IPF paving way for new Esbriet NDA

By Randy Osborne
Staff Writer

Tuesday, February 25, 2014
Intermune Inc. plans to resubmit its new drug application (NDA) for Esbriet (pirfenidone) for idiopathic pulmonary fibrosis (IPF) in the third quarter of this year, based on home run phase III data from a trial called ASCEND that sent the company’s shares into the upper altitudes.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription